Who is this vaccine for?

The FDA advisory committee recommended mRNA-1010 for adults aged 50 and older. Moderna is seeking full approval for those 50-64 and accelerated approval for those 65 and older.

What is an FDA advisory committee?

An FDA advisory committee is a panel of independent medical and scientific experts who review data for drugs and vaccines and provide recommendations to the FDA. The FDA typically considers these recommendations when making its final decision.

Why is an mRNA flu vaccine significant?

mRNA technology offers potential advantages over traditional flu vaccines, including faster development and manufacturing, which could allow for quicker adaptation to new flu strains each season. It also represents a major expansion of mRNA technology beyond COVID-19.

The FDA will now review the advisory committee's recommendation and all submitted data to make its final approval decision. This decision is expected by August 5, 2026.

Image: courtesy of Ars Technica

techJune 19, 2026By Veridact EditorialUpdated Jun 19

Moderna's mRNA Flu Shot Nears Approval After Unanimous FDA Advisory Vote

Moderna's mRNA-1010 flu vaccine candidate for adults aged 50 and older received a unanimous recommendation from a U.S. Food and Drug Administration (FDA) advisory committee yesterday. This marks a significant step for the company's efforts to expand its mRNA technology beyond COVID-19, particularly after earlier friction with the agency over study design. The FDA is expected to issue its final decision on the vaccine by August 5, 2026.

What to Expect

The unanimous vote from the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) is a strong signal that Moderna's mRNA-1010 vaccine is likely to receive full approval for adults 50 and older. The FDA typically follows the recommendations of its advisory committees, especially when the vote is unanimous. Once approved, Moderna would be able to launch its mRNA flu vaccine into a competitive market, potentially reshaping how seasonal influenza protection is delivered.

Consumers could see a new flu vaccine option available for the 2026-2027 flu season, particularly for older adults who often face higher risks from influenza. The approval could also accelerate the development and regulatory pathways for other mRNA-based vaccines currently in Moderna's pipeline and those from competitors, paving the way for a broader shift in vaccine technology.

Key Context

The FDA advisory committee's unanimous vote, which occurred yesterday, represents a critical milestone for Moderna, a company that rose to prominence during the COVID-19 pandemic on the strength of its mRNA technology. This particular candidate, mRNA-1010, is designed to protect against seasonal influenza in adults aged 50 and older. The committee's endorsement was for both full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, with a requirement for a post-marketing study in the older demographic.

The unanimous decision, with 16 votes in favor and none against, comes after a period of public disagreement between Moderna and the FDA earlier this year. Moderna had initially objected to the FDA's recommendations regarding the design of its clinical trials for mRNA-1010. The agency had suggested a specific comparative approach for the trials, which Moderna felt was not appropriate given its existing data. The company publicly stated its position, arguing that it had already provided additional comparison data from a separate trial that used a high-dose flu shot, often administered to older individuals, and that the FDA had not raised any safety concerns.

Ultimately, a resolution was found. Moderna proposed a revised regulatory strategy, which the FDA accepted. This revised approach involved seeking full approval for the younger segment of older adults (50-64) and accelerated approval for the oldest group (65+), coupled with a commitment to conduct a further study after the vaccine's potential market introduction. This willingness to find common ground allowed the review process to move forward, culminating in yesterday's positive advisory committee decision. This marks the first time since 2023 that the FDA's advisory committee has recommended a new vaccine, highlighting the significance of this particular approval cycle.

Historical Patterns

The U.S. Food and Drug Administration's advisory committees play a crucial role in the drug and vaccine approval process, offering independent expert opinions to the agency. While the FDA is not legally bound to follow these recommendations, it historically does so in the vast majority of cases, particularly when the vote is unanimous. A unanimous vote, like the 16-0 decision for Moderna's mRNA-1010, indicates a strong consensus among independent experts that the vaccine's benefits outweigh its risks based on the presented data.

Looking back, there are numerous precedents where unanimous or near-unanimous advisory committee votes have directly led to FDA approval. For instance, many of the COVID-19 vaccines received strong advisory committee backing before their emergency use authorizations and subsequent full approvals. Disagreements or split votes on advisory committees often lead to more scrutiny, requests for additional data, or even outright rejections. The absence of such dissent here suggests that the data presented by Moderna was compelling and addressed any lingering questions the committee members might have had about efficacy, safety, or the novel mRNA platform for a non-COVID vaccine.

Furthermore, the FDA's earlier friction with Moderna over trial design is not entirely unique in the history of drug development. Companies and regulatory bodies frequently engage in back-and-forth discussions regarding study protocols, data requirements, and statistical analyses. The fact that Moderna and the FDA were able to reach an agreement on a revised regulatory pathway, which then led to a successful advisory committee review, demonstrates the iterative nature of the regulatory process. It also indicates a pragmatic approach from both sides, ultimately prioritizing the assessment of a potentially important new public health tool.

The potential approval of Moderna's mRNA flu vaccine carries significant weight, extending far beyond a single product. For Moderna, it represents a crucial step in diversifying its revenue streams and proving the versatility of its mRNA platform. The company's market valuation surged during the COVID-19 pandemic, but as demand for COVID-19 vaccines normalizes, investors are keen to see Moderna successfully apply its technology to other prevalent diseases. A strong entry into the massive seasonal flu vaccine market would validate the company's long-term strategy and provide a stable, recurring revenue base.

For public health, this development could signal a fundamental shift in how flu vaccines are produced and administered. Traditional flu vaccines rely on egg-based or cell-based manufacturing, which can be time-consuming and limit flexibility in responding to evolving viral strains. mRNA technology offers the promise of faster development and production cycles, potentially allowing for more agile responses to new flu variants. This could lead to more effective vaccines each season, improving protection, especially for vulnerable populations like older adults, who are at higher risk of severe illness and complications from influenza.

Beyond influenza, the approval would further cement mRNA as a proven vaccine technology. It would likely accelerate research and development into mRNA vaccines for a wider array of infectious diseases, from RSV to HIV, and even certain cancers. This broader acceptance and regulatory experience with mRNA platforms could streamline future approvals, bringing new treatments to market faster. However, it also means traditional vaccine manufacturers will face increased competitive pressure to innovate or risk losing market share to these newer, more adaptable technologies.

Potential Outcomes

Analysis

The path forward for Moderna's mRNA-1010 vaccine now primarily rests with the FDA's final decision, expected by August 5, 2026. Given the unanimous advisory committee vote, several outcomes are possible, with varying degrees of likelihood.

One highly probable outcome is the full approval of mRNA-1010 for adults aged 50 to 64 and accelerated approval for those 65 and older. This would align directly with the advisory committee's recommendation and the revised regulatory strategy that Moderna and the FDA agreed upon. Such an approval would allow Moderna to launch the vaccine for the upcoming flu season, immediately entering the competitive landscape. This outcome suggests the FDA has found the efficacy and safety data sufficiently robust, especially after the prior discussions and data submissions.

Alternatively, the FDA could issue a conditional approval or request additional data before granting full approval. While less likely given the unanimous committee vote, the agency always retains the right to ask for more information or impose specific conditions, particularly for the accelerated approval pathway for the oldest age group. This could involve stricter post-marketing surveillance requirements or a more compressed timeline for the confirmatory study. Such a scenario might delay broad market availability or limit initial distribution, impacting Moderna's immediate commercial rollout plans.

A third, though significantly less probable, outcome would be a rejection of the vaccine application. This would be a rare move for the FDA following a unanimous positive advisory committee vote and would likely require the agency to identify substantial new concerns that were not apparent to the committee or to present a different interpretation of the existing data. Such a decision would send shockwaves through the industry, raising questions about the regulatory process and the future of mRNA vaccines beyond COVID-19. It would also represent a major setback for Moderna, forcing a re-evaluation of its flu vaccine program and broader mRNA expansion strategy.

Timeline

2026-06-18

FDA Advisory Committee Unanimously Recommends Approval

The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 16-0 to recommend approval for Moderna's mRNA-1010 flu vaccine for adults aged 50 and older.

2026-08-05

FDA Final Approval Decision Deadline

The U.S. Food and Drug Administration is expected to issue its final decision on Moderna's mRNA-1010 vaccine application by this date.

2026-09-01

Potential Vaccine Launch for Flu Season

If approved, Moderna may begin distributing mRNA-1010 for the 2026-2027 influenza season, targeting adults aged 50 and older.

Frequently Asked Questions

mRNA-1010 is Moderna's investigational seasonal influenza vaccine candidate, which uses messenger RNA (mRNA) technology. This is the same underlying technology used in Moderna's COVID-19 vaccine.

Discussion

Be the first to share your thoughts.